Eureka touts preclinical results for COVID-19 antibody nasal spray

By The Science Advisory Board staff writers

December 14, 2020 -- Eureka Therapeutics has touted positive preclinical results for its InvisiMask antibody nasal spray.

In a trial in mice, the spray offered protection against SARS-CoV-2 pseudotyped virus for up to 10 hours, according to Eureka Therapeutics. Results were published on the preprint server bioRxiv.

InvisiMask provides an intranasal application of a proprietary antibody thought to be prophylactic against COVID-19. It is designed to neutralize the novel coronavirus in airborne droplets and particles that enter the nasal cavity.

The antibodies were engineered with a proprietary adhesion technology developed to increase retention on respiratory mucosal surfaces, Eureka noted. The spray can also be both stored and used at room temperature.

Eureka is currently preparing to file an investigational new drug application with the U.S. Food and Drug Administration in order to conduct a clinical trial of the nasal spray.

Global health R&D stalls as resources are redirected to COVID-19
The current coronavirus pandemic has set back progress in research and development (R&D) on neglected diseases and other long-standing global health challenges...
Various updates for Pfizer, BioNTech COVID-19 vaccine post-EUA
Various announcements and updates regarding the Pfizer-BioNTech COVID-19 vaccine were made during the weekend and on Monday, December 14. These included...
FDA issues EUA for Pfizer, BioNTech COVID-19 vaccine
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine. The move comes after...
Pfizer, BioNTech's COVID-19 vaccine shows 95% efficacy
In a trial of more than 40,000 participants, Pfizer-BioNTech's COVID-19 vaccine showed a 95% efficacy against the SARS-CoV-2 virus, according to results...
New immunotherapy moves further into clinical testing with promising results
Success in international clinical trials leads to U.S. based research organizations beginning phase I/II clinical trials. If this form of immunotherapy...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter